If you have searched retatrutide price Australia in the last few months, you will have found a lot of numbers and almost no answers. That is because the number that will eventually matter to Australians is not a list price at all. It is a figure negotiated behind closed doors between a manufacturer and the Pharmaceutical Benefits Advisory Committee — and in April 2026, Eli Lilly walked away from exactly that kind of negotiation over a different drug.

That episode is the single most informative thing that has happened to Australian obesity-medicine pricing this year, and it has nothing to do with retatrutide's trial data. It is worth understanding before the next round begins.

Retatrutide price in Australia: why there isn't one yet

Retatrutide is Lilly's investigational triple agonist — it acts on GLP-1, GIP and glucagon receptors, which is one more target than tirzepatide (Mounjaro/Zepbound) and two more than semaglutide (Ozempic/Wegovy). You can read the mechanism in plain English on what is retatrutide.

It is not approved by the TGA, and it is not approved anywhere else either. Lilly has said it plans to submit a Biologics License Application to the US FDA in the first quarter of 2027, after posting positive Phase 3 results across the TRIUMPH programme — including the headline figure of up to roughly 28.3% average body weight loss at 12mg over 80 weeks in TRIUMPH-1. The full readout picture is summarised in our clinical trials overview.

So there is no Australian price because there is no Australian product. What there is, however, is a very recent worked example of how the pricing step actually goes.

The Mounjaro precedent: the PBAC said yes, Lilly said no

Tirzepatide had been knocked back for PBS listing in type 2 diabetes three times — July 2023, November 2024 and July 2025. At its March 2026 meeting, the PBAC finally recommended it be subsidised for adults with inadequately controlled type 2 diabetes.

Lilly declined.

In April 2026 the company said it would not proceed with the listing, citing among other grievances that the price the government was willing to pay was too low. As the ABC reported, the decision left roughly 450,000 Australians with type 2 diabetes without subsidised access to a medicine their own regulator's advisory committee had just recommended. Medicines Australia used the moment to argue the PBS assessment system itself is broken.

The relevance to retatrutide is direct rather than theoretical: same manufacturer, same committee, same country, same therapeutic area — and a demonstrated willingness to leave a positive recommendation on the table rather than accept the offered price.

What a PBS listing is actually worth to a patient

This is why the PBS step dominates everything else in the Australian cost of retatrutide question.

From 1 January 2026, the maximum a general Medicare card holder pays for a PBS-listed prescription is $25. For Commonwealth concession card holders it remains $7.70, and is legislated to stay there until 1 January 2030. That is the co-payment, not the medicine's price — the Commonwealth pays the rest.

Without a listing, the patient pays the full private price. The gap between those two scenarios is the entire ballgame, and it is decided by a negotiation, not by a trial result.

The narrow-door model the PBAC has already signalled

The PBAC's separate advice on equitable access to GLP-1 obesity treatments, delivered at its November 2025 meeting and published on 19 December 2025, is the other half of the picture. It did not recommend broad subsidised access. It recommended a "slow and managed roll-out" to manage uncertainty about long-term use and outcomes, and it named priority populations: people with established cardiovascular disease, Aboriginal and Torres Strait Islander patients with obesity-related comorbidities, people with syndromic obesity, people with medication-induced obesity, and patients needing weight loss to become eligible for surgery.

Notably, the committee also advised there should be no mandatory wraparound allied-health requirements attached to PBS-subsidised access, on the grounds that this would create a barrier for the people already at highest risk.

It is worth being precise about what this does and does not tell us. It does not tell us that retatrutide will be assessed on those terms — no submission exists. It does tell us the framework Australian obesity-medicine submissions are currently being judged against, and that framework is narrow by design.

Two gates, not one

For Australians tracking this drug, the practical takeaway is that there are two independent gates, and conflating them is the most common mistake in this search category:

  • TGA registration decides whether retatrutide can legally be sold here at all.
  • PBAC recommendation and PBS listing decides what an eligible patient pays.

A drug can clear the first and never clear the second. Tirzepatide is, right now, the local proof of that. For context on tolerability and the adverse-event profile reported across the trials, see our safety page.

We track each of these steps as it happens — join the free updates list and you'll get the Australian regulatory and reimbursement movements as they're confirmed, not as they're rumoured.

FAQ

How much will retatrutide cost in Australia?

No price exists yet. Retatrutide is not TGA-approved and Lilly has said it plans to file with the US FDA in the first quarter of 2027. Any Australian figure circulating now is not a confirmed price.

Will retatrutide be on the PBS?

There is no submission before the PBAC, so there is nothing to assess. The relevant precedent is that the PBAC recommended tirzepatide for type 2 diabetes in March 2026 and Lilly declined to proceed in April 2026, citing the price offered.

What do you pay for a PBS medicine in Australia in 2026?

From 1 January 2026, general Medicare card holders pay a maximum of $25 per PBS prescription. Concession card holders pay $7.70, which is legislated to remain unchanged until 1 January 2030.

Is retatrutide approved by the TGA?

No. Retatrutide remains investigational in Australia and in every other jurisdiction. Lilly's stated plan is to begin regulatory filings from 2027.

Sources

This article is for general information only and is not medical advice. Retatrutide is an investigational medicine that has not been approved by the TGA or any other regulator. Speak to your GP or a qualified health professional about weight management options available to you in Australia. Retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.